: Obtained Class 1 Innovative Drug Certificate for the Injection of Anrikfen

Hisico announced at noon on May 21st that the company received the category 1 innovative drug Anruifen Injection's "Drug Registration Certificate" issued by the National Medical Products Administration on May 21st. Anruifen Injection is a highly selective peripheral kappa opioid receptor agonist independently developed by the company, and is also the world's first non-narcotic analgesic drug with an indication for pain relief that does not need to be included in narcotic drug management on a prescription. It has significant clinical and social significance.